Dolly Varden Silver Co. (CVE:DV – Free Report) – Equities research analysts at Raymond James lowered their FY2024 EPS estimates for Dolly Varden Silver in a report released on Monday, September 30th. Raymond James analyst C. Stanley now expects that the company will post earnings of ($0.07) per share for the year, down from their prior forecast of ($0.06). Raymond James has a “Outperform” rating and a $1.60 price objective on the stock. The consensus estimate for Dolly Varden Silver’s current full-year earnings is $0.01 per share.
Separately, Haywood Securities upgraded Dolly Varden Silver to a “strong-buy” rating in a research note on Thursday, August 15th.
Dolly Varden Silver Stock Up 2.8 %
Shares of DV stock opened at C$1.12 on Wednesday. The company’s 50 day moving average is C$1.06 and its 200 day moving average is C$1.03. The firm has a market cap of C$348.01 million, a price-to-earnings ratio of -12.44 and a beta of 1.37. Dolly Varden Silver has a 52-week low of C$0.62 and a 52-week high of C$1.29.
Dolly Varden Silver (CVE:DV – Get Free Report) last posted its quarterly earnings results on Thursday, August 22nd. The company reported C($0.03) earnings per share for the quarter, missing the consensus estimate of C($0.02) by C($0.01).
Dolly Varden Silver Company Profile
Dolly Varden Silver Corporation engages in the acquisition and exploration of mineral properties in Canada. It explores for gold, silver, lead, zinc, and copper deposits. The company holds 100% interests in the Kitsault Valley project, which comprises the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada; and the Big Bulk property located in Canada.
See Also
- Five stocks we like better than Dolly Varden Silver
- Compound Interest and Why It Matters When Investing
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What Is WallStreetBets and What Stocks Are They Targeting?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Dolly Varden Silver Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolly Varden Silver and related companies with MarketBeat.com's FREE daily email newsletter.